← Back to Screener
MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)
Price$17.79
Favorite Metrics
Price vs S&P 500 (26W)94.04%
Price vs S&P 500 (4W)5.21%
Market Capitalization$1.29B
All Metrics
Book Value / Share (Quarterly)$4.27
P/TBV (Annual)55.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.75
Price vs S&P 500 (YTD)34.08%
EPS (TTM)$-3.52
10-Day Avg Trading Volume1.59M
EPS Excl Extra (TTM)$-3.52
EPS (Annual)$-3.53
ROI (Annual)-26.61%
Cash / Share (Quarterly)$5.52
ROA (Last FY)-24.88%
EBITD / Share (TTM)$-3.41
Cash Flow / Share (Annual)$-1.86
P/B Ratio4.25x
P/B Ratio (Quarterly)3.09x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-30.69x
ROA (TTM)-50.23%
EPS Incl Extra (Annual)$-3.53
Current Ratio (Annual)21.55x
Quick Ratio (Quarterly)8.77x
3-Month Avg Trading Volume1.85M
52-Week Price Return-49.59%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.93
52-Week High$62.75
EPS Excl Extra (Annual)$-3.53
26-Week Price Return98.02%
Quick Ratio (Annual)21.52x
13-Week Price Return-0.39%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.27x
Enterprise Value$1,032.119
Revenue / Employee (Annual)$0
Cash / Share (Annual)$7.11
3-Month Return Std Dev62.18%
Net Income / Employee (TTM)$-2
ROE (Last FY)-26.61%
Net Interest Coverage (Annual)-30.70x
EPS Basic Excl Extra (Annual)$-3.53
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-3.52
ROI (TTM)-55.15%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.25
Price vs S&P 500 (52W)-79.42%
Year-to-Date Return36.72%
5-Day Price Return-7.16%
EPS Normalized (Annual)$-3.53
Month-to-Date Return-3.33%
Cash Flow / Share (TTM)$-1.19
EBITD / Share (Annual)$-3.41
LT Debt / Equity (Quarterly)0.24x
EPS Basic Excl Extra (TTM)$-3.52
P/TBV (Quarterly)6.39x
P/B Ratio (Annual)7.74x
Book Value / Share (Annual)$7.10
Price vs S&P 500 (13W)-1.07%
Beta1.15x
Revenue / Share (TTM)$0.00
ROE (TTM)-67.12%
52-Week Low$5.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
3.75
3.78
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares | — | — | — | — | $17.79 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a tri-specific Nanobody that inhibits IL-17A and IL-17F to treat inflammatory skin and joint diseases. Clinical data suggest SLK has potential for disease modification in dermatology and rheumatology indications where IL-17A and IL-17F drive pathophysiology.